Timothé Cynober, Author at Labiotech.eu

About

Former regulatory scientist at Voisin Consulting Life Sciences in Paris. Currently working in business development at Institut Curie in big data, genomic and bioinformatic tech transfer and industrial partnerships. He describes himself as an innovative tech and therapies addict, interested in innovative health and digital tech, traveling, sports, video games and RPGs, and drawing.

Articles by Timothé Cynober

Single Cell Sequencing Precision Medicine

In Depth 27 Jan 2021

Single-Cell Sequencing: Paving the Way for Precision Medicine

Next-generation sequencing techniques to determine an individual’s unique genetic code gave rise to personalized treatments. Single-cell sequencing is the next step towards making precision medicine more accurate. Each cell in our body is unique. Even genetically identical cells can behave differently in response to a certain treatment. With next-generation sequencing, scientists can study how the […]

January 27, 2021 - 7 minutesmins - By Timothé Cynober

In Depth 21 Sep 2020

Why Are There Only 11 Cell and Gene Therapies in Europe?

There is a lot of talk about how cell and gene therapy are going to change medicine, so why have only a few of them reached the market? Over the last decade, only 15 advanced therapy medicinal products (ATMPs) – that is, cell and gene therapies – have received approval in Europe. With four withdrawals, […]

September 21, 2020 - 5 minutesmins - By Timothé Cynober

In Depth 27 Jul 2020

Biosensors: Monitoring Our Health Anywhere, Anytime

Biosensors are rapidly becoming part of our everyday life. As technology advances, we may soon be able to monitor many aspects of our health at home, in real time, and without needles. Traditionally used in medical practice to monitor patient status, biosensors have recently started to be broadly marketed for wellness and fitness applications. These […]

July 27, 2020 - 6 minutesmins - By Timothé Cynober

In Depth 1 Jun 2020

How Personal Genomics Companies Are Changing Drug Development

In recent years, companies offering direct-to-consumer genomics tests have started switching the business model and venturing into drug development. Amidst criticism on data protection and lack of transparency, personal genomics companies are leveraging their unique position to generate genomics data to strike lucrative deals with pharma companies. Thanks to cheaper data acquisition and convenient analysis, […]

June 1, 2020 - 6 minutesmins - By Timothé Cynober

In Depth 17 Jun 2019

Artificial Intelligence in Oncology: Fantasy or Reality?

Artificial intelligence promises to use the power of data to solve some of the biggest problems of our time. But can it help us treat a disease as complex as cancer? Artificial intelligence and machine learning are (not that) new technologies that have been recently boosted thanks to hardware improvements. Through algorithms, they can learn, […]

June 17, 2019 - 6 minutesmins - By Timothé Cynober

In Depth 11 Feb 2019

CRISPR: One Patent to Rule Them All

The gene editing tool CRISPR-Cas9 has revolutionized research in biology. With several parties fighting for the rights to the technology’s intellectual property, how difficult is it for third parties to access this coveted technology? The CRISPR patent dispute is quite unique. While universities usually work together to disseminate innovation and knowledge, in the CRISPR case […]

February 11, 2019 - 5 minutesmins - By Timothé Cynober

In Depth 14 May 2018

Could Stem Cells Replace Animal Testing in Drug Development?

Animal testing is a crucial part of developing new medicines, but it comes with ethical concerns. Stem cells could eventually make it unnecessary. Nowadays you can order a rat with Parkinson’s disease or a dog with diabetes as you would any product on the internet. But the ethical issues surrounding animal testing beg the question: […]

May 14, 2018 - 6 minutesmins - By Timothé Cynober

News and Trends 20 Dec 2017

How to Deal with Regulations to Get Approval for CAR-T Cells

The biotech industry is diving into the field of highly individualized gene and cell therapy products. The first CAR-T therapy has just been approved in the US and other breakthrough technologies like mRNA and CRISPR have a foot in the door. But getting to the market is not straightforward, not only for developers but also for […]

December 20, 2017 - 8 minutesmins - By Timothé Cynober

SHIVA Trial Precision Medicine Cancer France

In Depth 20 Jul 2017

SHIVA Trial: France’s Big Shot at Precision Medicine for Cancer

SHIVA01 and SHIVA02 are large-scale trials run in France to evaluate the efficacy of precision medicine that have created ripples in the oncology field. Although molecular alterations are shared among different types of cancer, drug development today is still mainly based on tumor localization. The only recent exception is MSD’s Keytruda (pembrolizumab) an antibody approved by […]

July 20, 2017 - 5 minutesmins - By Timothé Cynober

In Depth 12 Jul 2017

Genomic Testing in Oncology: From Single Genes to Whole Genomes

Personalized medicine would be nothing without genomic testing tools. Here’s an overview of how the field has rapidly evolved in the past years. BRCA (BReast CAncer) is one of the most famous gene variants for breast cancer testing. But aside from being a game-changer from a scientific perspective, it also changed the laws of genomic testing. […]

July 12, 2017 - 5 minutesmins - By Timothé Cynober

News and Trends 14 Jun 2017

Results are in for Europe’s First Biobanking Study on HPV Cervical Cancer

The RAIDs consortium made its closing event last week. After 4.5 years of studies, it has managed to change our appreciation of HPV cervical cancer towards building intelligent targeted therapy designs. Every year in Europe, 16,000 women die from cervical cancer and another 34,000 are newly diagnosed, which makes it the second most frequent form […]

June 14, 2017 - 5 minutesmins - By Timothé Cynober

News and Trends 18 Jan 2017

It’s Not Just Regulations: 9 Other Reasons Advanced Therapies Fail

For advanced therapy medicinal products (ATMPs), the regulatory process is a major challenge to reach the market; but it’s only part of the picture. Here are the top 9 other pre-approval reasons these cell and gene therapies fail. Sound Scientific Rationale + Good Product = Successful Outcome.” Paula Salmikangas, Committee for Advanced Therapies (CAT) Chairman […]

January 18, 2017 - 7 minutesmins - By Timothé Cynober

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us